Effects of EGR rate on performance and emissions of a diesel power generator fueled by B7

This paper analyses the impacts of the application of an exhaust gas recirculation (EGR) system on the performance and emissions of a stationary, direct-injection diesel engine operating with diesel oil containing 7% biodiesel (B7). Experiments were carried out in a 49-kW diesel power generator with the adapted EGR system, and engine performance and emissions were evaluated for different load and EGR settings. The results were compared with the engine operating with its original configuration without the EGR system, and revealed a reduction of peak cylinder pressure and fuel conversion efficiency, mainly at high engine loads. The use of EGR caused opposite effects on carbon dioxide (CO2), carbon monoxide (CO) and total hydrocarbons (THC) emissions, depending on load and EGR rate, showing an increase in most situations. The application of EGR consistently reduced oxides of nitrogen (NOX) emissions, reaching a maximum reduction close to 30%. In general, the use of EGR increased CO2, CO and THC emissions at high loads. The use of 7.5% EGR was found to be at an adequate rate to simultaneously reduce CO, THC and NOX emissions at low and moderate loads, without major penalties on CO2 emissions and engine performance

International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional Approach

Chronic obstructive pulmonary disease (COPD) and asthma are the most common inflammatory respiratory diseases related to an increase in mortality and morbidity. Generally, bronchodilators, ß- agonists, anticholinergics and theophylline used for treatment in these conditions and administered by inhalation for delivery, have localized and systematic effects. The adverse effects are due to pharmacodynamic and pharmacokinetic changes and especially drug-drug and drug-disease interactions. However, phytotherapy is classical and widespread throughout the world for the treatment of ailments. This chapter highlights cellular and molecular mediators involved in COPD and asthma, the shortcomings of current therapies and the emerging need of phytomedicines. Phytomedicine supports respiratory physiology, bronchial action and possesses antioxidants to maintain homeostasis